Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Thyroid Tests Covered by Four New BCBS Plans

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyGenX and ThyraMir molecular thyroid tests have received coverage from four additional Blue Cross Blue Shield plans.

The ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier are used to diagnose thyroid nodules with indeterminate cytology. According to Interpace, both tests are now covered by Blue Cross Blue Shield of Arizona, Blue Cross Blue Shield of South Carolina, Wellmark Blue Cross Blue Shield of Iowa, and Wellmark Blue Cross Blue Shield of South Dakota. The four payors represent more than 5 million members combined.

"The coverage of ThyGenX and ThyraMir by these additional Blue Cross Blue Shield plans is further evidence that we have met the clinical utility threshold required to secure reimbursement for these tests," Interpace President and CEO Jack Stover said in a statement.

Interpace said that its thyroid tests are now covered for over 280 million patients nationwide, including through Medicare, Medicare Advantage, and national and regional health plans.

The Scan

Transplant Tests Edited Pig Kidneys

The Associated Press reports a University of Alabama-Birmingham team transplanted genetically modified pig kidneys into a brain-dead human patient.

UK Changes Some Gene-Edited Crop Rules

A new law may enable gene-edited crops to be sold in the UK within about five years, New Scientist says.

Pill Works Against Omicron in Lab

Pfizer's antiviral pill to treat SARS-CoV-2 appears to work against the Omicron variant, the Wall Street Journal reports.

Nature Papers Find Genetic Risk Factor for Smell, Taste Loss in COVID-19; Analyze TB Granulomas

In Nature this week: genome-wide association study find locus linked to the risk COVID-19 patients losing their sense of taste or smell, and more.